SNFGE SNFGE
 
Thématique :
- Cancer colorectal (CCR)
Originalité :
Intermédiaire
Solidité :
Très solide
Doit faire évoluer notre pratique :
Dans certains cas
 
 
Nom du veilleur :
Professeur Thomas APARICIO
Coup de coeur :
 
 
Gut
  2018/12  
 
  2018 Dec. pii: gutjnl-2018-317293.  
  doi: 10.1136/gutjnl-2018-317293.  
 
  Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report.  
 
  Senore C, Basu P, Anttila A, Ponti A, Tomatis M, Vale DB, Ronco G, Soerjomataram I, Primic-Žakelj M, Riggi E, Dillner J, Elfström MK, Lönnberg S, Sankaranarayanan R, Segnan N  
  https://www.ncbi.nlm.nih.gov/pubmed/30530530  
 
 

Abstract

OBJECTIVE:

To present comparative data about the performance of colorectal cancer (CRC) screening programmes in the European Union Member States (EU MSs).

DESIGN:

Cross-sectional study. We analysed key performance indicators-participation rate, positivity rate (PR), detection rate (DR) and positive predictive value for adenomas and CRC-based on the aggregated quantitative data collected for the second EU screening report. We derived crude and pooled (through a random effects model) estimates to describe and compare trends across different MSs/regions and screening protocols.

RESULTS:

Participation rate was higher in countries adopting faecal immunochemical test (FIT) (range: 22.8%-71.3%) than in those using guaiac faecal occult blood test (gFOBT) (range 4.5%-66.6%), and it showed a positive correlation (ρ=0.842, p<0.001) with participation in breast cancer screening in the same areas. Screening performance showed a large variability. Compliance with referral for colonoscopy (total colonoscopy (TC)) assessment ranged between 64% and 92%; TC completion rate ranged between 92% and 99%. PR and DR of advanced adenomas and CRC were higher in FIT, as compared with gFOBT programmes, and independent of the protocol among men, older subjects and those performing their first screening.

CONCLUSIONS:

The variability in the results of quality indicators across population-based screening programmes highlights the importance of continuous monitoring, as well as the need to promote quality improvement efforts, as recommended in the EU guidelines. The implementation of monitoring systems, ensuring availability of data for the entire process, together with initiatives aimed to enhance reproducibility of histology and quality of endoscopy, represent a priority in screening programmes management.

 

 
Question posée
 
Existe-t-il des différences de performance concernant les programmes de dépistage du cancer colorectal selon les pays européens ?
 
Question posée
 
Oui.
 
Commentaires

Le dépistage par test immunologique apparait plus efficace que le dépistage par test au guaiac. Cependant, les différences d’organisation entre les pays apparaissent comme un facteur explicatif fondamental.

 
www.snfge.org